Company intelligence / Profile preview

Sequence LifeScience

San Antonio, Texas, United States

Ownership: Private
Development stage: Other

Overview

Sequence LifeScience is conducting a multicenter prospective matched controls clinical trial investigating placental-derived allografts for the treatment of diabetic foot ulcers. The trial, expected to begin recruiting in July 2025, seeks to generate robust comparative data on healing rates and safety using a novel trial design with historic matched controls. Prior studies on placental membranes as wound covers show promising benefits in wound healing, antimicrobial, and anti-inflammatory activity.

Therapeutic areas: EndocrinologyDermatologyOther
Modalities: Biologic
Industry: Biotech

Drug pipeline

1 asset

AmnioDefend

Unknown

Partnerships

SerenaGroup Inc.

Beyond the preview

Go deeper on Sequence LifeScience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sequence LifeScience.

Explore the full profile